The House Judiciary Committee has launched an investigation into the timing of Pfizer’s COVID-19 vaccine development, as we understand it today. The inquiry stems from alleged statements made by a former Pfizer scientist, Dr. Philip Dormitzer.
According to reliable sources, Dr. Dormitzer reportedly claimed involvement in efforts to “deliberately slow down” vaccine testing until after the 2020 presidential election. The committee is now seeking documentation from both Pfizer and Dr. Dormitzer to verify these assertions.
The panel has requested an interview with Dr. Dormitzer by May 29, though no subpoena has been issued at this time. Pfizer, for its part, maintains that the vaccine development was “driven by science and guided by the U.S. FDA back in 2020,” refuting any allegations of political motivation.
The background to this situation is important. Dr. Dormitzer, who joined GSK in 2021, allegedly expressed concerns about potential investigations into the vaccine’s release, requesting relocation to Canada. GSK reported these comments, leading to a federal probe in New York last year.
This development follows earlier reports that nine pharmaceutical companies, including Pfizer, pledged not to seek government approval until their vaccines were proven safe and effective. The Pfizer vaccine’s efficacy was publicly announced on November 8, 2020, one day after Joe Biden was declared the winner of the presidential election.
The significance of this inquiry should not be overlooked. It raises important questions about the intersection of medical science and political processes. Both sides present compelling arguments, with House Republicans suggesting potential election influence, while Pfizer staunchly defends the integrity of its scientific process.
As this story continues to unfold, it is crucial to remember that the facts, as we now know them, are still emerging. The public’s right to accurate information remains paramount, and we will continue to report on this developing situation as more details come to light.
